Alkermes to Take Part in Stifel's 3rd Annual CNS Day

Rhea-AI Summary

Alkermes plc (Nasdaq: ALKS) will participate in a virtual fireside chat at Stifel's 3rd Annual CNS Day on April 1, 2021, at 8:30 a.m. ET. The event will be accessible on the company's website and archived for 14 days. Alkermes is a biopharmaceutical company developing medicines for neuroscience and oncology, with a portfolio focused on addiction and schizophrenia. Their pipeline includes candidates for schizophrenia, bipolar I disorder, neurodegenerative disorders, and cancer.

Positive

• Participation in Stifel's 3rd Annual CNS Day indicates proactive engagement with investors.
• Strong pipeline development for neurological and cancer treatments demonstrates innovative focus.

Negative

• None.

DUBLIN, March 25, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at Stifel's 3^rd Annual CNS Day on Thursday, Apr. 1, 2021 at 8:30 a.m. ET (1:30 p.m. BST). The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

About Alkermes plc

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Contact:
Alex Braun
Investor Relations
+1 781 296 8493

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/alkermes-to-take-part-in-stifels-3rd-annual-cns-day-301256281.html

SOURCE Alkermes plc

FAQ

When is Alkermes participating in Stifel's 3rd Annual CNS Day?

Alkermes will participate in Stifel's 3rd Annual CNS Day on April 1, 2021, at 8:30 a.m. ET.

Where can I access the Alkermes presentation from the CNS Day?

The presentation can be accessed under the Investors tab on Alkermes' website and will be archived for 14 days.

What is Alkermes' focus in drug development?

Alkermes develops innovative medicines in neuroscience and oncology, focusing on addiction and schizophrenia.

What kind of products does Alkermes have in its pipeline?

Alkermes has product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders, and cancer.